Location History:
- Groebenzell, DE (2009 - 2010)
- Gröbenzell, DE (2012 - 2015)
Company Filing History:
Years Active: 2009-2015
Title: Wolfgang Schmalix: Innovator in Pharmaceutical Formulations
Introduction
Wolfgang Schmalix, a distinguished inventor based in Gröbenzell, Germany, has made significant contributions to the field of pharmaceuticals. With four patents to his name, Schmalix is recognized for his innovations that focus on the treatment of serious medical conditions, particularly those related to cancer and neurodegenerative diseases.
Latest Patents
Among his latest patents, Schmalix developed a stable dosage form of phenylalanine derivatives. This invention relates to improved and stable pharmaceutical formulations of these compounds, which serve as urokinase inhibitors. These formulations are particularly promising for the treatment of malignant tumors and tumoral metastases. Another notable patent focuses on the use of urokinase inhibitors for the treatment and prevention of neuropathological diseases. This invention presents novel methods and compositions for addressing neurodegenerative conditions, offering innovative solutions for diseases such as amyotrophic lateral sclerosis.
Career Highlights
Wolfgang Schmalix is currently affiliated with Wilex AG, a company that specializes in the development of innovative cancer therapeutics. His role at Wilex AG has allowed him to pioneer research and applications that directly impact patient care and treatment efficacy in oncology.
Collaborations
Throughout his career, Schmalix has collaborated with various experts in his field, including notable coworkers Stefan Sperl and Markus Buergle. These partnerships have fostered an environment of shared knowledge and innovation, further enhancing the impact of their collective research efforts.
Conclusion
In summary, Wolfgang Schmalix stands out as a forward-thinking inventor whose work continues to push the boundaries of pharmaceutical science. His contributions not only bring new treatments to the medical community but also inspire future research and development in the fight against cancer and neurodegenerative diseases.